Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Taps Emergent BioSolutions to Help Manufacture Its COVID-19 Vaccine

By Brian Orelli, PhD – Apr 23, 2020 at 9:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The contract is worth $135 million to Emergent BioSolutions.

Johnson & Johnson (JNJ -0.71%) signed a contract to pay Emergent BioSolutions (EBS 1.01%) $135 million to help manufacture its vaccine to treat COVID-19, the disease caused by the novel coronavirus.

In addition to developing its own drugs aimed at combating bioterrorism and emerging infectious diseases, including COVID-19, Emergent BioSolutions has a contract manufacturing division that makes drugs for other companies. Last month, the company announced that it was working with Novavax to develop its COVID-19 vaccine.

Johnson & Johnson's vaccine hasn't even entered clinical trials: The study is scheduled to start in September with initial supply for the phase 1 clinical trial to come from Johnson & Johnson's manufacturing facility in Leiden, the Netherlands.

Gloved hands giving an injection into a patient's shoulder

Image source: Getty Images.

But the deal with Emergent BioSolutions is clearly a sign that Johnson & Johnson is trying to get ahead of its goal of having 1 billion doses available. Emergent BioSolutions will begin manufacturing Johnson & Johnson's vaccine this year, well ahead of any potential approval, and Emergent BioSolutions plans to reserve large-scale manufacturing capacity to make the vaccine next year.

Johnson & Johnson noted that the deal with Emergent BioSolutions was just the "first in a series of anticipated strategic collaborations" to meet the global supply of its vaccine.

"We have set a high bar. Johnson & Johnson has committed to rapidly produce and supply more than one billion doses of a safe and effective vaccine globally," said Paul Stoffels, vice chairman of the executive committee and chief scientific officer at Johnson & Johnson, in a statement.

Perhaps Johnson & Johnson should hit up Pfizer (PFE -0.91%), which has committed its manufacturing capabilities for therapies or vaccines to treat or prevent the disease. Pfizer is also developing a vaccine of its own in conjunction with BioNTech.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$163.36 (-0.71%) $-1.17
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$20.99 (1.01%) $0.21
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.20 (-1.99%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.